Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHT 2: tepotinib with or without osimertinib in MET-amplified EGFR-mutant advanced NSCLC after acquired resistance to first-line osimertinib
jRCT2080224898Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of tepotinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by EMD Serono. Started Sep 2019; status: completed.
02
Drugs
tepotinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224898.